ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد

Human papillomavirus infections: Epidemiology and disease associations

Human papillomavirus infections: Epidemiology and disease associations
Author:
Joel M Palefsky, MD
Section Editor:
Martin S Hirsch, MD
Deputy Editor:
Nicole White, MD
Literature review current through: Apr 2025. | This topic last updated: Feb 25, 2025.

INTRODUCTION — 

Papillomaviruses are double-stranded deoxyribonucleic acid (DNA) viruses that constitute the Papillomavirus genus of the Papillomaviridae family. These viruses are highly species specific; human papillomaviruses (HPVs) infect only humans. There are more than 200 types of HPVs, which can be subdivided into cutaneous or mucosal categories based upon their tissue tropism.

The epidemiology and disease associations of HPV infections will be reviewed here. The role of HPV in the pathogenesis of epithelial cancers is discussed elsewhere. (See "Virology of human papillomavirus infections and the link to cancer".)

The clinical manifestations, diagnosis, and management of HPV-associated diseases are discussed in the dedicated topic reviews.

Vaccination to prevent HPV infection and its associated diseases is also discussed elsewhere. (See "Human papillomavirus vaccination".)

MICROBIOLOGY

Replication cycle — HPVs are small, nonenveloped, capsid viruses with an eight kilobase circular genome that encodes eight genes, including two encapsulating structural proteins, L1 and L2 [1]. The L1 protein, expressed recombinantly in a cell-culture system, self-assembles in the absence of the viral genome to form a virus-like particle (VLP). The L1 VLP is the immunogen used in the HPV vaccines. L2 is the minor capsid protein that along with L1 mediates HPV infectivity [1,2].

The replication cycle of the virus is integrally linked to epithelial differentiation (ie, the maturation of the keratinocyte). Initial infection of the basal stem cell occurs as the result of microscopic breaks in the epithelium [3,4]. The infecting HPV virions appear to attach to the basal stem cell via tissue-specific heparan sulfate proteoglycans [5-7].

Specific gene products are transcribed at every level of differentiation of the squamous keratinocyte [3]. At the most superficial level, the genes for the L1, L2, and E4 genes are transcribed for assembly of the viral capsid into which the HPV genome is packaged. Upon desquamation of this short-lived cell, infectious HPV virions are released for the next round of infection.

Natural history — Most HPV infections, including those with carcinogenic HPV genotypes, typically resolve within 12 months [8,9]. During productive cervical HPV infection, low-grade cytologic abnormalities may be clinically detectable in screening but are usually transient. However, carcinogenic HPV infections that persist beyond 12 months increase the likelihood of precancerous or cancerous lesions, although not all persistent infections progress [10]. In the United States, the median age of cytologically detected precancerous cervical lesions occurs approximately 10 years after the median age of sexual debut [11].

HPV can enter a latent state [12-14]. Additionally, there is evidence of cervical viral reactivation in some populations, including females with human immunodeficiency virus (HIV), older females, and females with a history of cervical dysplasia [15-17]. However, it is unknown whether all or only a subset of HPV infections become latent and whether re-emergent HPV infections carry a significant cancer risk.

Genotypes and tissue tropism — Different HPV types have a propensity to infect different body sites and are thus associated with different diseases (table 1). (See 'Disease associations' below.)

●Cutaneous – Certain HPV types have a predilection for cutaneous epithelium and are found in plantar warts, common warts, flat warts, and butcher's warts (common warts that tend to occur in meat, poultry, and fish handlers) [18]. HPV types associated with plantar and common warts include types 1, 2, and 4. Flat warts are most often caused by HPV types 3 and 10, while butcher's warts are most often associated with HPV types 7 and 2 [19]. (See 'Nongenital warts' below.)

●Anogenital epithelium – HPV types with a predilection for anogenital keratinized skin and mucous membrane infection also exist. Common sites for infection include the penis, scrotum, perineum, anal canal, perianal region, vaginal introitus, vulva, and cervix. Over 40 mucosal HPV genotypes can infect the genital tract. Anogenital disease manifestations differ by HPV type:

•Genital warts (condyloma acuminatum) – These are benign anogenital warts, caused most often by HPV types 6 and 11 [20,21]. (See 'Genital warts' below.)

•Squamous intraepithelial lesions and/or carcinoma of the vagina, vulva, cervix, anus, or penis – Approximately 15 HPV types are associated with cancer and are known as high risk, carcinogenic, or cancer associated [22]. HPV 16 is the most common and is associated with the highest risk of progression to cancer [19,20,23-26]. (See 'Cervical cancer' below and 'Vulvar and vaginal cancer' below and 'Anal cancer' below and 'Penile cancer and precursor lesions' below.)

The presence of a cervical transformation zone is not necessary for oncogenic HPV to infect the female genital tract. As a result, the prevalence of oncogenic HPV subtypes in the vagina is similar in females who have and have not undergone hysterectomy [27]. Similarly, HPV may infect not only the anal canal in the anal transformation zone, but also more distal sites, including the keratinized skin of the anal verge and perianal region [28,29]. (See "Virology of human papillomavirus infections and the link to cancer".)

●Other mucosal surfaces – HPV type 16 can infect the oral mucosa and has been associated with squamous cell carcinoma of the oropharynx. Infection of the respiratory mucosa with HPV types 6 and 11 also occurs, particularly but not exclusively in young children and infants [20]. (See 'Oropharyngeal cancer' below and 'Recurrent respiratory papillomatosis' below.)

DISEASE ASSOCIATIONS

HPV-related disease in females

Cervical cancer — Worldwide, cervical cancer is the fourth most common cancer among females, with approximately 604,000 cases of invasive cervical carcinoma diagnosed and 342,000 cervical cancer deaths annually [30,31]. (See "Virology of human papillomavirus infections and the link to cancer" and "Cervical intraepithelial neoplasia: Terminology, incidence, pathogenesis, and prevention" and "Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis".)

Evidence linking HPV to cervical carcinoma is extensive [19,23,24,32]. Virtually all cases of cervical cancer are attributable to HPV infection, with HPV 16 and 18 accounting for the majority of cancers [33]. Other high-risk HPV subtypes are detailed in the table (table 2). The epidemiology of high-risk types can be illustrated by the following observations:

●A pooled analysis of 11 case-control studies from nine countries involving 1918 females with histologically confirmed squamous cell cervical cancer and 1928 controls was performed to better determine the risk associated with various HPV genotypes [34]. HPV DNA was found in 90 percent of the females with cervical cancer and 13 percent of controls. Fifteen HPV types were classified as high risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82).

●A study of paraffin-embedded samples representing 10,575 cases of invasive cervical cancer from 38 countries spanning five continents demonstrated that the most common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58; HPV types 16 and 18 represented 71 percent of the cases overall [35].

●A systematic review including almost 112,000 HPV-positive cervical cancers from 121 countries identified 17 HPV subtypes that are causal to cervical cancer [33]. The distribution of HPV subtypes for the two most common histologic types of cervical cancer (squamous and adenocarcinoma) are detailed separately. (See "Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Histopathology'.)

Although HPV 16 and 18 are the dominant HPV types in cervical cancer globally, there is some regional variation in the less frequent HPV types associated with cervical cancer. This has important implications for the design of HPV vaccines to maximize the number of cancers prevented in these regions. Next-generation HPV vaccines will likely include some of these less-frequently detected HPV types, in addition to the seven high-risk HPV types currently included in the nonavalent HPV vaccine.

A detailed discussion of other risk factors for cervical cancer is found elsewhere. (See "Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Epidemiology'.)

Vulvar and vaginal cancer — Vulvar and vaginal cancer are uncommon globally. Unlike cervical cancer, not all cancers of the external genitalia are associated with HPV infection. The attributable fraction due to HPV infection has been estimated to be 29 to 43 percent for vulvar cancer, 87 percent for vulvar intraepithelial neoplasia, 70 percent for vaginal cancer, and 69 to 100 percent for vaginal intraepithelial neoplasia [36-40]. HPV types 16 and 18 cause approximately 35 to 77 percent of HPV-positive vulvar cancer, 75 to 80 percent of HPV-positive precancerous vulvar lesions, and 60 percent of HPV-positive vaginal cancer and precancerous vaginal lesions [37,38].

In contrast to HPV-negative cancers of the external genitalia, HPV-associated vulvar cancers occur at a younger age, exhibit basaloid instead of keratinizing pathology, do not have p53 mutations, and are associated with sexual risk factors [41,42]. HPV-associated vaginal cancers have similar features, but overall, vaginal cancer is more likely to be HPV-associated [40,43].

The epidemiologic link of HPV infection to these cancers is discussed in detail elsewhere. (See "Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment", section on 'Epidemiology' and "Vaginal cancer", section on 'Epidemiology and risk factors'.)

HPV-related disease in females and males

Nongenital warts — HPV is spread from skin surface to skin surface, and cutaneous HPV infections are widespread throughout the general population. Warts occur in 10 percent of children, with a peak incidence between the ages of 12 and 16 [44]. Nongenital warts are not confined solely to the pediatric population; as many as 3.5 percent of adults have nongenital warts at any given time [20]. Common warts represent up to 71 percent of all cutaneous warts followed in frequency by plantar warts and flat warts (34 and 4 percent, respectively) [19]. Close personal contact is assumed to be of importance for the transmission of cutaneous warts [19]. (See "Cutaneous warts (common, plantar, and flat warts)".)

Genital warts — Population-based studies in sexually active individuals suggest a prevalence ranging from 1 percent in the United States to approximately 10 percent in Scandinavian countries [44-47]. The peak prevalence occurs in persons between the ages of 17 and 33 years of age, and the peak incidence is in those aged 20 to 24 years. (See "Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Epidemiology'.)

HPV types 6 and 11 cause approximately 90 percent of genital warts. In a study of 8800 females who were enrolled in the placebo arms of two HPV vaccine trials, approximately 3 percent developed genital warts over four years, and the vast majority were associated with HPV 6 or 11 infection [48].

In children, anogenital warts are associated with HPV types typically isolated from common warts (types 1 and 2). (See "Condylomata acuminata (anogenital warts) in children".)

Anal cancer — Anal cancer is relatively uncommon among the general global population, although its incidence has been increasing in some resource-abundant settings, including the United States [30,49-51]. In the United States, anal cancer is now more common than cervical cancer among White females 65 years of age and older. HPV types 16 and 18 cause nearly 90 percent of anal cancers and precancerous anal lesions (ie, high-grade squamous intraepithelial lesions) [50-54].

Females have a higher incidence of anal cancer than males, although incidence is particularly high among men who have sex with men, particularly those with HIV [55-57].

The epidemiologic link of HPV infection to anal cancer is discussed in detail elsewhere. (See "Anatomy, pathology, epidemiology, and risk factors of anal cancer", section on 'Human papillomavirus infection'.)

Oropharyngeal cancer — HPV infection plays a role in the pathogenesis of squamous cell carcinomas of the head and neck. Like penile and vulvar cancer, oropharyngeal cancers consist of two broad categories of disease: HPV-associated and non-HPV-associated. HPV-associated oropharyngeal cancers are primarily found in the oropharynx and base of the tongue and tonsil [58-60]. HPV has also been linked to cancer of the larynx [61]. (See "Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer".)

HPV-related oropharyngeal cancers occur in a younger population than the non-HPV-associated cancers and are associated with sexual risk factors [62,63]. In contrast, non-HPV-associated cancers are associated primarily with alcohol and tobacco use and often have p53 mutations. In the United States, the incidence of HPV-associated oropharyngeal cancers has been rising and the incidence of non-HPV-associated cancers has been declining, so that the incidence of the former now exceeds that of the latter [49,63]. In 2015, oropharyngeal squamous cell carcinoma was the most common HPV-associated cancer [64].

In an age- and sex-matched case-control study of 130 patients with newly diagnosed squamous cell carcinoma of the head and neck, oropharyngeal malignancy was associated with high-risk sexual behaviors, oropharyngeal HPV infection, and HPV 16 seropositivity [58].

The prevalence and incidence of oropharyngeal HPV infection is discussed below. (See 'Epidemiology of oropharyngeal infection' below.)

Recurrent respiratory papillomatosis — Recurrent respiratory papillomatosis is the most common benign laryngeal tumor in children and is thought to be caused by HPV acquired during passage through the birth canal of an infected mother [65]. HPV 6 and 11 are the types most commonly involved. The incidence is uncertain but has been estimated at 4.5 per 100,000 children and 1.8 per 100,000 adults in the United States. Although benign, substantial morbidity arises from obstruction of the larynx by the warts, and many affected children require multiple ablative procedures [65,66]. In addition, the papillomatous lesions can, rarely, grow aggressively, spread into the lungs, and undergo malignant transformation.

This condition is discussed in further detail elsewhere.

Other cutaneous diseases

●Bowen's disease, a form of high-grade intraepithelial neoplasia, has both genital and extragenital forms [67]. It can occur on the fingers, toes, palms, feet, and on the genital mucosa. Multiple HPV types have been isolated from these lesions, including HPV types 16, 18, 31, 32, 34, and others [18,23,67]. (See "Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis", section on 'Cutaneous squamous cell carcinoma in situ (Bowen disease)'.)

●Epidermodysplasia verruciformis is a rare, probably autosomal recessive condition characterized by the appearance of HPV-induced wart-like lesions early in childhood, with malignant transformation in approximately half of patients during adulthood, often in skin surfaces with sun exposure. Multiple HPV types have been isolated from these lesions, but HPV types 5 and 8 appear to have the most malignant potential in these individuals [68]. (See "Epidermodysplasia verruciformis".)

HPV-related diseases in males

Penile cancer and precursor lesions — Penile cancer is uncommon globally, although in some parts of Africa, South America, and Asia, it accounts for up to 10 percent of male cancers [69,70]. Unlike cervical cancer, not all cancers of the external genitalia are associated with HPV infection. HPV types 16 and 18 cause approximately 35 to 40 percent of penile cancers overall and 70 to 80 percent of HPV-positive penile cancers [71]. In contrast to HPV-negative cancers of the external genitalia, HPV-associated penile cancers occur at a younger age, exhibit basaloid instead of keratinizing pathology, do not have p53 mutations, and are associated with sexual risk factors [41,42].

The epidemiologic link of HPV infection to these cancers is discussed in detail elsewhere. (See "Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'HPV'.)

DETECTION OF HPV — 

The clinical application of human papillomavirus (HPV) detection includes cervical and vaginal swabs for the testing of cervical cancer [72], oropharyngeal biopsy specimens for oropharyngeal cancer, and anal swabs for anal cancer [73,74]. Vaginal swabs are approved in the United States for self-sampling and many European nations utilize self-sampling as part of their national cervical cancer screening. Penile swabs and oral rinses are not approved for routine use of cancer detection in most countries but are used for surveillance and research purposes.

More information on the techniques for HPV detection are discussed in detail elsewhere. (See "Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing", section on 'HPV testing' and "Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Confirming HPV 16 positivity'.)

HPV testing to determine appropriateness of HPV vaccination is not warranted [73].

The detection of HPV is facilitated by advances in molecular biology. HPV DNA testing was the first approach developed for routine clinical testing. Many studies showed that the addition of HPV DNA testing to cervical cytology improved the sensitivity for detection of cervical cancer precursors, such as cervical intraepithelial neoplasia (CIN) 2 and 3. However, this may come at the cost of decreased specificity with the potential for unnecessary referral of some females for colposcopy. Several different HPV DNA detection assays have been validated and are approved for clinical use in screening [75].

HPV ribonucleic acid (RNA) testing, looking for expression of E6 and/or E7 RNA, may be performed with the expectation that active HPV oncogene expression would provide similar sensitivity and slightly better specificity than HPV DNA testing [76]. RNA-based testing is US Food and Drug Administration (FDA)-approved for cervical HPV testing [75].

Cellular marker detection uses a different approach to diagnosing HPV-associated disease. The HPV E7 protein disrupts cell cycling, leading to an increase in cellular p16 protein expression. Per the recommendations of the Lower Anogenital Tract Terminology project [77], CIN 2 or anogenital biopsy specimens classified as grade 2 can be stained with p16 immunostain. Those that are positive are classified along with CIN 3 biopsies as high-grade squamous intraepithelial lesions. CIN 2 biopsies negative for p16 are classified as low-grade squamous intraepithelial lesions. p16 immunostaining of cervical biopsies is also used to help distinguish between high-grade CIN and immature squamous metaplasia, which is not associated with HPV and is not precancerous.

p16 staining, along with Ki-67 staining, is also used in cytology specimens. A large study investigating the combination p16/Ki-67 dual-stained cytology has demonstrated superior sensitivity and noninferior specificity over conventional liquid-based or slide-based cervical cytology to detect cervical high-grade squamous intraepithelial lesions dysplasia [78]. A p16/Ki-67 cytology-based test is FDA approved for screening and is typically used in conjunction with HPV testing to determine the need for referral for colposcopy and to guide other management decisions. (See "Cervical cancer screening: The cytology and human papillomavirus report", section on 'Management of results'.)

Several other methods of screening are under active investigation, including detection of HPV E6 oncoproteins [79] and host and HPV methylation assays [80-82]. The goal of incorporating these assays is to use them in combination with HPV testing or cytology to maximize the sensitivity and specificity and negative and positive predictive value of screening algorithms designed to identify females in need of colposcopy or other forms of further evaluation. The exact indication and the order of use of these tests are still under investigation in different populations. In addition, the various testing methods are being assessed for use in self-sampling specimens, since self-sampling may allow females to participate in screening programs more easily than provider-collected sampling allows [83].

EPIDEMIOLOGY OF ANOGENITAL INFECTION — 

Globally, anogenital HPV is the most common sexually transmitted infection. Like all sexually transmitted infections, peak prevalence of HPV infection typically occurs within the first decade after sexual debut, typically between the ages of 15 to 25 years in most western countries.

There are more than 40 HPV types that infect the entire lower genital tract, including the vagina [4,5,84,85]. It has been estimated that at almost all sexually active individuals will acquire HPV at some point in their lifetime [86]. Most HPV infections are transient and can come and go in the interval between HPV testing.

Impact of HPV vaccine — Routine HPV immunization is recommended in many countries for adolescents and young adults. The data demonstrate that the HPV vaccine has resulted in a very substantial reduction in HPV prevalence among vaccine-eligible-aged individuals [87-108]. The decline of HPV prevalence in vaccinated and unvaccinated individuals demonstrates the efficacy of direct and herd protection [103,104,109-112].

Many studies have reported declining prevalence and incidence of HPV infection as well as HPV-related disease following the introduction of HPV vaccination [89-105]. As an example, in the United States, the prevalence of quadrivalent HPV vaccine types 6, 11, 16, and 18 in cervical samples from females from the prevaccine (2003 to 2006) and postvaccine (2013 to 2016) eras decreased by 88 percent (from 11.5 to 1.1 percent) among those aged 14 to 19 years and by 81 percent (from 18.5 to 3.3 percent) among those aged 20 to 24 years [106]. This observation was made despite suboptimal vaccine coverage, with only an estimated 55 percent of adolescent females receiving at least one vaccine dose. Similarly in another study of participants within a large United States health care system, HPV vaccine type prevalence decreased 78 percent among 20- to 24-year-olds and 38 percent in 25- to 29-year-olds within 9 to 10 years of vaccine introduction [107]. In these and other studies, declines in vaccine-type HPV infections have been observed in both vaccinated and unvaccinated individuals, showing evidence of direct and herd protection [103,104,109-112]. In another analysis, the prevalence of quadrivalent HPV types (6/11/16/18) among sexually-experienced vaccination-age non-Hispanic White women declined 82 percent in the 2015 to 2018 time period compared with the 2003 to 2006 time period prior to the introduction of the vaccine [108]. Among sexually experienced non-Hispanic Black women, and Mexican American women, those declines were 86 percent and 100 percent respectively. The declines in the prevalence of the other 5 HPV types in the nonavalent HPV vaccine (HPV 31, 33, 45, 52 and 58), were smaller, but still substantial, at 51 percent, 23 percent, and 55 percent among non-Hispanic White women, non-Hispanic Black women and Mexican American women, respectively. The lower reduction in nonavalent HPV vaccine types not found in the quadrivalent vaccine compared with quadrivalent vaccine types likely reflects the later introduction of the nonavalent vaccine, which was recommended by the Advisory Committee on Immunization Practices (ACIP) in 2015. Further declines in the prevalence of the five additional HPV types included in the 9-valent HPV vaccine are expected to become evident with further time since the introduction of that vaccine.

The data show that the benefits of vaccination are being seen across underrepresented groups in the United States. However, ensuring uniformly high vaccine uptake among vaccine-eligible girls is still a work in progress. Compared with White girls, Black and Hispanic girls were more likely to initiate vaccination while Asian girls were less likely to do so [113], but girls of underrepresented groups were less likely to complete the vaccination series compared with White girls [87,88]. (See "Human papillomavirus vaccination", section on 'Cervical, vaginal, and vulvar disease'.)

The impact of HPV vaccination on HPV-associated disease is discussed in detail elsewhere. (See "Human papillomavirus vaccination", section on 'Efficacy'.)

Females

Genital infections

United States — Incidence of HPV infection was high among young sexually active females soon after their sexual debut [114-116]. One study of female college students reported a 29 percent one-year cumulative incidence of HPV infection following their first male sexual partner; this increased to almost 50 percent after three years [115]. Many sexually active young females have sequential infections with different oncogenic types of HPV. These infections are usually detected transiently, although they frequently produce reversible cytologic changes. However, introduction of HPV vaccination has been associated with declines in HPV prevalence and incidence (see 'Impact of HPV vaccine' above and "Human papillomavirus vaccination", section on 'Efficacy'). Consequently the epidemiology of HPV has changed substantially since the introduction of the HPV vaccine among populations that have high vaccine uptake. Among populations with low HPV vaccine uptake, it is likely that the epidemiology of HPV infection would remain relatively unchanged.

Prior to the introduction of the HPV vaccine, there were racial differences in the type and turnover of HPV infection in females [117-119]. These differences are illustrated by the findings of a longitudinal study of 467 college-age females in the United States [118]. The overall incidence of HPV infection was similar between Black and White females, but Black females had a slightly higher incidence of infection with high-risk HPV types. Two years after the incident high-risk HPV infection, more Black females had persistent infection (56 versus 24 percent of White females). These findings might partially explain the higher incidence of cervical cancer in Black females in the United States (see "Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Incidence and mortality'). With the impact of HPV vaccination being demonstrated across underrepresented groups [108], it is possible that these disparities will be reduced in the future, but this will require ongoing efforts to maximize vaccine uptake and vaccine series completion across all underrepresented groups and regions in the United States. Overall, HPV vaccine coverage with ≥1 dose was 75.1 percent among adolescents in 2020 and the percentage of adolescents who were up to date with HPV vaccination was 58.6 percent [120].

Worldwide — A meta-analysis of studies including over 150,000 females with normal cervical cytology demonstrated that the worldwide point-prevalence of HPV is approximately 10 percent [121]. The highest regional prevalence was in Africa, where 22 percent of females had evidence of HPV infection. Similar to the United States, the epidemiology of HPV infection worldwide is expected to change as more countries adopt routine HPV vaccination and as access to and uptake of the vaccine improves. However, global uptake among vaccine-eligible girls continues to remain low; in 2020 global coverage with two doses of the vaccine was only 13 percent [122].

The most common types worldwide are HPV types 16 and 18, both of which are preventable by vaccination; however, there appears to be geographic variation in the distribution of HPV genotypes. As an example, in an HPV prevalence study from 11 countries that included over 15,000 sexually active females with normal cervical cytology, females in Europe with HPV infection were more likely to be infected with HPV type 16 compared with those in Sub-Saharan Africa (odds ratio [OR] 2.6) [123].

In a study of 1275 females aged 12 to 24 years seeking health services in Uganda, the prevalence HPV and HIV infections was 75 and 9 percent, respectively [124]. Among high-risk types, the most frequently detected were HPV types 52 (13 percent), 51 (12 percent), 18 (11 percent), and 16 (11 percent).

In contrast, in a study of 2185 sexually active females recruited from universities in the United Kingdom, the prevalence of high-risk HPV infection, detected by testing of self-collected vaginal swabs, was 19 percent [125]. Among those with high-risk HPV infection, HPV type 16 was the single most common type detected, but most of the females were infected with at least one non-16, non-18 HPV type.

Older females — In unvaccinated populations, the prevalence of cervical HPV infection decreases sharply in females after the age of 25 [126]. A secondary, minor peak of HPV prevalence has been observed in some populations after menopause [22,127]. In China and Africa, the prevalence of HPV remains uniformly high at all ages [128]. The cause of this is unknown.

Among older females, the prevalence of HPV detection might be related to persistence or reactivation of previously acquired infection rather than new, recent infections. In a cohort of over 800 females aged 35 to 60 years, the attributable risk for high-risk HPV detection associated with a history of more than five lifetime sexual partners was greater than that associated with a new sexual partner among females older than 50 years (87 versus 8 percent) [129]. In contrast, among females 35 to 49 years of age, the attributable risks associated with lifetime and recent sexual partners were the same (28 percent). That this reflects reactivation of infection in older females is only one interpretation of the data, but raises important questions about the cause and importance of reactivation HPV [13,130,131]. Reactivation has also been proposed as a major source of newly detected HPV infection among females with HIV. In a prospective study of 1848 females with HIV (the Women's Interagency HIV Study), more than half of the females with newly detected cervical HPV infection had reported no new sexual partners since the prior visit [132].

Anal infections — Studies of anal HPV infection in females suggest that it is far more common than originally thought [133-137]. In studies of high-risk females, including females with HIV and females with a history of commercial sex work or injection drug use, anal HPV infection is more common than cervical HPV infection [137-140]. In studies of lower-risk females, the prevalence and incidence of anal HPV infection is similar to that of cervical HPV infection, and longitudinal studies have demonstrated that acquisition of cervical HPV infection predicts acquisition of anal HPV infection [134,141-143]. Similarly, in a systematic review of studies involving over 13,000 females with paired cervical and anal samples, there was a strong relationship between cervical HPV infection and anal HPV infection [143]. Females with a history of vulvar or cervical high-grade, squamous intraepithelial lesions or cancer are also at increased risk of anal HPV infection and HPV-related disease [143].

Despite the frequency of anal HPV infections in females, they are often transient [133,144]. In one study of 431 sexually active females, half of whom had incident anal HPV infections, more than 58 percent became HPV DNA test-negative over a 15-month period of follow-up [133]. This observation may help explain why the incidence of anal cancer is much lower than that of cervical cancer [145].

Risk factors for infection — Genital and cervical HPV infections are primarily transmitted by genital-genital or anal-genital contact [146]. The most consistent predictor of genital HPV infection has been sexual activity [146]. Most studies have been performed in young females in whom the following findings have been noted:

●The risk of cervicovaginal HPV infection in females is directly related to the number of male sex partners [45,114,147-152] and to the male partners' number of female sex partners [148].

●As with other sexually transmitted infections, sex with a new partner is a stronger risk factor than sex with a long-term partner [114,151]. In a prospective cohort study of young females in San Francisco, for example, the relative hazard was 10.1 per new partner per month [151].

Both vaginal and anal intercourse are major risk factors for HPV infection [146]. Although penetrating vaginal intercourse is not required for transmission [114], the prevalence of HPV infection is much lower among virgins (4 versus 22 percent in sexually active females in a report from Sweden) [150]. In one study of adolescent females with no reported history of sex, genital HPV infection was noted in 8 percent and was associated with intravaginal cleansing, but this observation could simply reflect unreported or nonpenetrating sexual activity [153,154].

Anal intercourse is likely an efficient means of spread of HPV to the anal canal, but it is similarly not required for transmission; other types of contact may also play a role in transmission, such as spread through fingers or toys, or from other genital organs infected with HPV [114,155,156]. In one study from Australia, anal HPV infection was associated with post-toilet wiping from front to back, implying that direct spread of HPV from one genital site to another through wiping could account for some cases of anal HPV infection not associated with anal intercourse [157].

Among heterosexual couples, type-specific concordance (ie, both partners infected with the same HPV type) is common, almost 25 percent in one series [158]. Additionally, among discordant heterosexual couples, female to male transmission may occur at a higher rate than male to female transmission [159]. Transmission in either direction is typically asymptomatic [45,160].

In several studies of females, the presence of anti-HPV antibodies, indicative of prior infection, has been associated with a decreased risk of subsequent infection with HPV of the same type, particularly for type 16, suggesting the potential for protective immunity following natural infection [161-164]. However, the extent and duration of such protection is unknown, and many females do not develop antibodies following infection [165-167].

Correct and consistent condom use reduces the risk of HPV infection [168]. However, condoms do not completely prevent transmission of HPV because the virus is spread through skin-to-skin contact.

Although use of an intrauterine device has been associated with a lower risk of cervical cancer, it does not appear to be associated with either the acquisition or clearance of genital HPV infection [169]. (See "Intrauterine contraception: Candidates and device selection", section on 'Infection risk'.)

Males — Global HPV prevalence in males appears to be around 30 to 35 percent [170,171]. A consistent finding among demographic groups is an association between increased sexual activity and high-risk HPV genotypes. Among males in the United States, based on data collected from participants in the 2013 to 2014 NHANES, for which male participants would submit penile swabs for HPV DNA testing, the prevalence of genital HPV infection was estimated to be 45 percent for all types and 25 percent for high-risk types [172]. These are only point-prevalence estimates; lifetime risk of genital HPV infection is much higher.

Factors associated with prevalent HPV infection in males include HIV infection, current and past sexual behavior, number of sex partners, absence of condom use, prior sexually transmitted infection, race, ethnicity, and circumcision status [173-180]. Natural history studies demonstrate that uncircumcised males have slower rates of HPV clearance compared with circumcised males [181].

Men who have sex with men — The burden of anogenital HPV infection among men who have sex with men (MSM) is high [177,179,182], including among teenaged and young MSM under 30 years [183-185]. In a meta-analysis of 53 observational studies, the pooled prevalence for anal infection with any HPV type and any high-risk HPV type in MSM without HIV was 64 and 37 percent, respectively [179]. The largest of these studies evaluated 1218 MSM without HIV between the ages of 18 and 89 years in four American cities [182]. Demographic data and information on sexual practices were collected, and specimens from the anal canal were tested for the presence of HPV infection by polymerase chain reaction. The following findings were noted:

●The overall prevalence of anal HPV infection was 57 percent.

●Prevalence did not vary across age groups.

●The most common HPV type was HPV 16, a high-risk type for anal cancer.

In a multivariate analysis, anal HPV infection was independently associated with a history of receptive anal intercourse (OR 2) and with more than five sex partners during the preceding six months (OR 1.5). Another study that assessed the baseline prevalence of penile, scrotal, perineal, and intra-anal HPV infections among 602 MSM without HIV found anal infections to be the most common site of involvement (42 percent) [177]. Published data from the placebo arm of an HPV vaccine study show that the prevalence of HPV 6, 11, and the 7 most common high-risk HPV infections was 37.9 percent, among MSM aged 16 to 26 years [186]. Risk factors for HPV seropositivity in this group included younger age at sexual debut, higher number of receptive anal sex partners, and less frequent condom use.

Among males with HIV, the prevalence of anal HPV infection appears to be even higher. (See 'Effect of HIV infection on HPV' below.)

Heterosexual males — HPV genital infection is common among heterosexual males, as shown by the findings of several studies, including the human papillomavirus in men study, which follows a large prospective cohort of males without HIV from the United States, Mexico, and Brazil:

●Among 3326 heterosexual males, the prevalence of genital HPV of any type was 53 percent [187]. Almost one-third of study participants were infected with oncogenic HPV types. Factors associated with oncogenic HPV infection included smoking, heavy alcohol use, and a higher numbers of female sexual partners, whereas condom use was associated with a reduced likelihood of HPV infection.

●The 12-month incidence of genital HPV among 1159 males (approximately 90 percent of whom were heterosexual) was 39 and 27 percent for any type and oncogenic types, respectively [188]. The overall median time to clearance of HPV infection was 7.5 months, although it was one year for HPV type 16.

Other, smaller studies of males in the United States have shown comparable HPV rates and associated factors [189-191]. These rates may differ in various regions of the world. A study of 776 heterosexual males without HIV in rural Uganda reported a high incidence of oncogenic genital HPV infection (33 cases per 100 person-years) [192]. The risk of infection decreased with age, married status, and circumcision; condom use had no association. In another study of 3463 heterosexual males from Latin America, North America, Africa, Europe, and Asia, the prevalence of genital HPV was 21 percent for any type, although fewer types were tested for in this study [176]. Neither condom use nor circumcision was associated with HPV infection. The prevalence of HPV was lowest in Asia and highest in Africa. Published data from the placebo arm of a HPV vaccine study show that the prevalence of HPV 6, 11, and the 7 most common high-risk HPV infections was 13.1 percent among heterosexual males aged 16 to 26 years [186].

Few studies have evaluated the frequency of anal HPV infection in heterosexual males, but it appears to be less than that of genital HPV infection. In a meta-analysis, the prevalence of anal HPV16 and overall high-risk HPV was 2 percent and 7 percent, respectively, in men without HIV who have sex with women and 9 and 27 percent, respectively, in men with HIV who have sex with women [193].

Risk factors for anal HPV infection included increased lifetime number of female sex partners, shorter duration of relationship with the current sex partner, prior genital HPV infection, and past diagnosis of hepatitis B virus infection [175,194].

The high rates of infection in these study populations suggest that strategies for the prevention of HPV infection, such as HPV vaccination, also need to target males. (See "Human papillomavirus vaccination", section on 'Males'.)

Effect of circumcision — A meta-analysis of 23 studies was performed to assess the association between circumcision and HPV DNA [195]. Circumcised males were less likely to have prevalent genital HPV infection than uncircumcised males (OR 0.57, 95% CI 0.45-0.71). There was weak evidence that circumcision was associated with decreased HPV incidence or increased HPV clearance.

Effect of HPV sampling sites — The epidemiology of HPV may also be affected by the specific genital sites that are sampled within studies; this issue is most controversial among males because of conflicting data on optimal HPV detection.

A systematic analysis of optimal HPV sampling in a prevalence study evaluated the site-specific prevalence of infection (eg, urethra, glans penis/coronal sulcus, penile shaft/prepuce, scrotum, perianal region, anal canal, semen, and urine) [196]. HPV detection was highest at the penile shaft (50 percent) and lowest in the urethra and in semen (10 and 5 percent, respectively). Another prevalence study of 379 males also demonstrated a wide range of infection rates depending on the site sampled (eg, 6 percent in semen to 52 percent on the penile shaft) [197].

The findings were different in the incidence study [190]. Sampling of the glans, penile shaft, and scrotum demonstrated that genital infection in males is multifocal and that there is no clear preferential site for infection. HPV DNA was also detected under fingernails; however, it is unclear as to whether this observation has significant implications for transmission.

EPIDEMIOLOGY OF OROPHARYNGEAL INFECTION — 

The prevalence of oropharyngeal human papillomavirus (HPV) is generally lower than that of anogenital HPV infection [60,172,198-201]. Also, consistent with the observed sex distribution for HPV-associated oropharyngeal cancer, the prevalence of oropharyngeal HPV infection in males is higher than in females. In a cross-sectional study of males and females who provided an oral rinse sample for HPV DNA sampling, the prevalence of oropharyngeal infection among 4493 males was 11.5 percent for any HPV type and 7.3 percent for high-risk HPV types; among the 4641 females, the prevalence was 3.2 and 1.4 percent, respectively [201]. The prevalence of high-risk HPV infection was especially high (22.2 percent) among males reporting two or more lifetime same-sex oral sex partners.

Oropharyngeal HPV prevalence has been associated with a greater number of sexual (including oral sex) and open-mouthed kissing partners in both males and females, as well as with older age and smoking (both tobacco and marijuana) [60,198,201-203].

The incidence of oropharyngeal HPV is also lower than that of anogenital HPV infection. In a study of 1626 males aged 18 to 70 years (88 percent men who have sex with women only) without a prior history of HPV-associated disease and with a median follow-up of 13 months, 4.4 percent acquired an oropharyngeal infection with any HPV type, and 1.7 percent with an oncogenic HPV type [204]. The incidence of oropharyngeal HPV infection was 5.6 and 2.5 cases per 1000 person-months for any and oncogenic types, respectively, and was constant across all age groups. In multivariate analysis, acquisition of a new oncogenic oropharyngeal HPV infection was associated with former or current smoking and being unmarried, but not with number of sexual partners or oral sex partners. Of the infections with enough longitudinal follow-up, 45 of 81 (56 percent) oral infections with any type and 18 of 24 (75 percent) infections with oncogenic types spontaneously cleared, at a median of six to seven months.

There is evidence that upper aerodigestive tract (nasal and oropharyngeal) HPV infection may be acquired in the health care setting through exposure to HPV in aerosols produced during surgical excision or ablation of HPV-associated lesions, although the magnitude of this risk is unknown [205]. HPV DNA has been detected in surgical smoke generated following laser or electrocoagulation treatment of cutaneous and cervical lesions [206,207]. Smoke generated during laser ablation of bovine fibropapillomas caused new cutaneous lesions when injected into calves, suggesting the viability of infectious papillomavirus in surgical smoke [208], but this has not yet been specifically demonstrated for HPV. Clinical evidence also supports the possibility of transmission of HPV through surgical smoke. As an example, in a study of 700 gynecologists in China who underwent nasal swab testing for HPV, self-report of performing electrosurgery or loop electrosurgical excision procedures was associated with a higher prevalence of HPV (9 to 10 percent compared with 2 to 3 percent) [209]. However, none of those gynecologists with an initial positive test subsequently had detectable nasal HPV DNA over 24 months of follow-up, and none were diagnosed with HPV-associated upper aerodigestive tract disease. Nevertheless, HPV-associated upper aerodigestive tract disease has been reported in several surgeons with long histories of treating HPV-related lesions and no other clear risk factors [210,211]. Potential interventions to prevent occupational exposure to HPV are discussed elsewhere. (See "Human papillomavirus vaccination", section on 'Health care workers at risk for occupational exposure' and "Cervical intraepithelial neoplasia: Diagnostic excisional procedures", section on 'Health care workers at risk for occupational exposure'.)

There is emerging evidence that HPV vaccination can protect against oropharyngeal HPV infection [212-214]. (See "Human papillomavirus vaccination", section on 'Oropharyngeal disease'.)

INTERACTIONS BETWEEN HIV AND HPV — 

There is a bidirectional epidemiologic interaction between HIV and HPV infections.

Effect of HIV infection on HPV — Several studies have shown that HPV infection is more common among individuals with HIV than in those without HIV [137,179,193,215-218].

Infection with multiple HPV types is also more common among individuals with HIV. In a study of 486 heterosexual South African couples followed for up to 24 months, new HPV infection was detected more frequently in females with HIV (57 versus 27 events per 1000 person-months) and males with HIV (80 versus 52 events per 1000 person-months) compared with individuals without HIV [217]. Furthermore, HIV infection was independently associated with a decreased likelihood of clearance of HPV infection over time.

Another study evaluated the concordance of HPV infection among 254 heterosexually active couples and the impact of HIV coinfection on the prevalence of HPV [216]. The following observations were made:

●HPV detection was significantly more common among females with HIV than among females without HIV (68 versus 31 percent, respectively).

●Similarly, HPV detection was significantly more common among males with HIV than among males without HIV (72 versus 43 percent, respectively).

●HIV coinfection in one partner had a significant impact on the prevalence of HPV infection in the other partner. For example, HIV-uninfected male partners of females with HIV had a greater prevalence of HPV than did HIV-uninfected male partners of females without HIV (58 versus 32 percent, respectively).

●Concordance of the same HPV genotypes was more commonly found among couples when one or both partners had HIV, compared with couples without HIV.

Among men who have sex with men (MSM), anal HPV prevalence is similarly increased in the setting of HIV infection [179,219-222]. In a meta-analysis of 64 studies, the prevalence of anal HPV 16 and overall high-risk anal HPV infection was considerably higher in males with HIV (29 and 74 percent respectively, compared with 14 and 41 percent in MSM without HIV) [193].

The use of effective antiretroviral therapy (ART) may attenuate the risk of HPV infection and persistence among patients with HIV [218,223-225], although data are conflicting [226]. As an example, in a study of 652 females with HIV, among whom the baseline prevalence of high-risk HPV was 42 percent, ART use and HIV RNA suppression for more than two years were each independently associated with a lower risk of high-risk HPV infection [223]. Sustained HIV RNA suppression was also marginally associated with clearance of high-risk HPV infection (odds ratio [OR] 1.02, 95% CI 1.001-1.04). Other studies have not shown an association between ART use and decreased HPV risk [227]. The effect of ART on the risk of HPV-associated neoplasia is discussed elsewhere. (See "Preinvasive and invasive cervical neoplasia in patients with HIV infection", section on 'Antiretroviral therapy' and "Anal squamous intraepithelial lesions: Epidemiology, clinical presentation, diagnosis, screening, prevention, and treatment", section on 'HIV'.)

Effect of HPV on HIV acquisition — HPV infection is associated with an increased risk for HIV acquisition. Whether HPV infection itself predisposes to subsequent HIV infection or is simply a marker of increased HIV risk remains unknown. It is also unclear whether prevalent HPV infection or the immune response associated with clearing that HPV infection, or both, plays a role in potentiating HIV acquisition.

The first evidence for an association between HPV infection and increased risk of HIV acquisition came from studies of MSM. In a cohort of MSM without HIV, infection with more than one anal HPV type was significantly associated with HIV seroconversion (adjusted hazard ratio [HR] 3.5, 95% CI 1.2-10.6) [228]. Subsequent studies suggest that penile HPV infection is also a risk factor for subsequent HIV infection [229]. Males without HIV in Kenya (n = 2168) who were participating in a randomized trial of male circumcision underwent HPV DNA sampling of their glans/coronal sulcus and were followed up for 42 months for evidence of HIV acquisition [229]. Approximately 50 percent of the males had evidence of HPV DNA at baseline. After controlling for subsequent circumcision status, baseline herpes simplex virus type 2 serostatus, and other sexual risk factors, those males who were infected with HPV at baseline had a significantly higher risk of HIV acquisition compared with males without HPV infection (HR 1.8, 95% CI 1.1-2.9).

In contrast, in a case-control study of 44 males who acquired HIV and 787 males without HIV who had been followed in a circumcision trial, penile HPV acquisition was not associated with HIV acquisition after controlling for other HIV transmission risks [230]. However, an association between clearance of HPV infection and subsequent HIV infection was observed in this study and postulated to be related to changes in local immune responses that might predispose to HIV infection.

The presence of HPV infection also appears to be associated with an increased risk of HIV acquisition among females. In a meta-analysis of prospective studies of females who underwent HPV testing, HIV acquisition was associated with baseline HPV infection of any type and high-risk type (HRs 2.06 [95% CI 1.44-2.94] and 1.99 [95% CI 1.54-2.56], respectively) when compared with no baseline HPV infection [231]. Of note, several included studies did not assess or adjust for sexual behavior or other coincident sexually transmitted infections, which are significant potential confounders in the association between HPV and HIV. In a separate study of females from Zimbabwe, clearance of cervical HPV infection was associated with risk of HIV acquisition [232], similar to the association with clearance of penile HPV infection described in the study above. Similarly, in a clinical trial of HIV chemoprophylaxis among cisgender women in sub-Saharan Africa, HPV infection was associated with an increased risk of HIV seroconversion [233].

INFORMATION FOR PATIENTS — 

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

●Basics topics (see "Patient education: Human papillomavirus (HPV) (The Basics)" and "Patient education: Human papillomavirus (HPV) vaccine (The Basics)")

●Beyond the Basics topics (see "Patient education: Human papillomavirus (HPV) vaccine (Beyond the Basics)" and "Patient education: Genital warts in women (Beyond the Basics)" and "Patient education: Cervical cancer screening (Beyond the Basics)")

SUMMARY

●Microbiology − Human papillomaviruses (HPV) are double-stranded DNA viruses that only infect humans. There are more than 200 types of HPV, which differ in their tissue tropism (table 1). HPV can be transmitted from one epithelial surface to another. Most infections typically resolve within 12 months. However, persistent infection with high-risk HPV types can increase the risk of precancerous or cancerous lesions. (See 'Microbiology' above.)

●Genotypes and disease associations − Cutaneous infection with HPV types 1 and 2 is associated with plantar or common hand warts. Mucocutaneous infection with HPV types 6, 11, 16, and 18 is associated with genital warts and precancerous and cancerous lesions of the cervix, vulva, vagina, penis, anus, and oropharynx. Evidence linking HPV to cervical carcinoma is extensive, with HPV 16 accounting for approximately 50 percent of invasive cervical cancers, and HPV 18 for 20 percent. (See 'Genotypes and tissue tropism' above and 'Disease associations' above.)

●Detection of HPV − Clinical application of HPV detection is limited to testing cervical specimens and oropharyngeal cancer biopsy specimens. Although HPV testing of other sites has been used for surveillance and research purposes, there is no clinical utility to such testing, and we do not recommend it. (See 'Detection of HPV' above.)

●Anogenital infections − Anogenital HPV is the most common sexually transmitted infection. In the pre-HPV vaccination era, and in populations with low HPV vaccination rates, peak prevalence of HPV infection typically occurs within the first decade after sexual debut. The worldwide prevalence of genital HPV infection among females is approximately 10 percent, and HPV type 16 is the most common high-risk type. Penile HPV infection is also highly prevalent among males, and anal infection is common among females and men who have sex with men. Persons with multiple sex partners are at greater risk for HPV infection compared with those in a monogamous relationship, and individuals with a new sex partner are at greater risk than those with a long-term sex partner. HPV vaccination has led to substantial declines in the prevalence of HPV infection and HPV-associated disease, particularly in populations with high vaccine uptake. (See 'Impact of HPV vaccine' above and "Human papillomavirus vaccination", section on 'Efficacy' and 'Epidemiology of anogenital infection' above.)

●Oropharyngeal HPV − The prevalence of oropharyngeal HPV infection is higher in males than in females but is overall lower than that of anogenital infection. Oropharyngeal HPV infection is also associated with sexual risk factors. (See 'Epidemiology of oropharyngeal infection' above.)

●Interaction between HIV and HPV − HPV detection is more common among individuals with HIV than among those without HIV. HPV infection is associated with an increased risk of HIV acquisition. Whether HPV infection itself predisposes to subsequent HIV infection or is simply a marker of increased HIV risk remains unknown. (See 'Interactions between HIV and HPV' above.)

  1. Yang R, Yutzy WH 4th, Viscidi RP, Roden RB. Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem 2003; 278:12546.
  2. Yang R, Day PM, Yutzy WH 4th, et al. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol 2003; 77:3531.
  3. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110:525.
  4. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167.
  5. Johnson KM, Kines RC, Roberts JN, et al. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 2009; 83:2067.
  6. Selinka HC, Florin L, Patel HD, et al. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 2007; 81:10970.
  7. Shafti-Keramat S, Handisurya A, Kriehuber E, et al. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 2003; 77:13125.
  8. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582.
  9. Rodríguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513.
  10. Sierra MS, Carvajal LJ, Dull P, et al. Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT). Vaccine 2025; 50:126841.
  11. Castle PE, Fetterman B, Akhtar I, et al. Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol 2009; 114:365.
  12. Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J 2012; 6:190.
  13. Hammer A, de Koning MN, Blaakaer J, et al. Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans. Papillomavirus Res 2019; 7:82.
  14. Doorbar J. The human Papillomavirus twilight zone - Latency, immune control and subclinical infection. Tumour Virus Res 2023; 16:200268.
  15. Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115:1150.
  16. Malagón T, MacCosham A, Burchell AN, et al. Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. Clin Infect Dis 2022; 75:365.
  17. Hammer A, Blaakaer J, de Koning MNC, et al. Evidence of latent HPV infection in older Danish women with a previous history of cervical dysplasia. Acta Obstet Gynecol Scand 2022; 101:608.
  18. Carr J, Gyorfi T. Human papillomavirus. Epidemiology, transmission, and pathogenesis. Clin Lab Med 2000; 20:235.
  19. Bonnez W, Reichman RC. Papillomaviruses. In: Principles and Practice of Infectious Diseases, Fifth Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingston, Philadelphia 2000. p.1630.
  20. Beutner KR. Nongenital human papillomavirus infections. Clin Lab Med 2000; 20:423.
  21. von Krogh G, Lacey CJ, Gross G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000; 76:162.
  22. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890.
  23. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001; 164:1017.
  24. Sedlacek TV. Advances in the diagnosis and treatment of human papillomavirus infections. Clin Obstet Gynecol 1999; 42:206.
  25. Thomas DB, Ray RM, Koetsawang A, et al. Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. Am J Epidemiol 2001; 153:723.
  26. Tilston P. Anal human papillomavirus and anal cancer. J Clin Pathol 1997; 50:625.
  27. Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190:458.
  28. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120.
  29. Stier EA, Goldstone SE, Einstein MH, et al. Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS 2013; 27:545.
  30. HPV Information Centre. Human Papillomavirus and Related Diseases Report. https://hpvcentre.net/statistics/reports/XWX.pdf (Accessed on April 25, 2022).
  31. Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary Report 10 March 2023. https://hpvcentre.net/statistics/reports/XWX.pdf (Accessed on June 25, 2024).
  32. Sonnex C. Human papillomavirus infection with particular reference to genital disease. J Clin Pathol 1998; 51:643.
  33. Wei F, Georges D, Man I, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet 2024; 404:435.
  34. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518.
  35. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048.
  36. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5:F12.
  37. de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49:3450.
  38. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626.
  39. Chao A, Jao MS, Huang CC, et al. Human papillomavirus genotype in cervical intraepithelial neoplasia grades 2 and 3 of Taiwanese women. Int J Cancer 2011; 128:653.
  40. Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009; 113:917.
  41. Hoevenaars BM, van der Avoort IA, de Wilde PC, et al. A panel of p16(INK4A), MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma. Int J Cancer 2008; 123:2767.
  42. Chaux A, Cubilla AL. The role of human papillomavirus infection in the pathogenesis of penile squamous cell carcinomas. Semin Diagn Pathol 2012; 29:67.
  43. Bibby DC, Grimble RF. Effects of urethane, ambient temperature and injection route on rat body temperature and metabolism due to endotoxins. J Physiol 1988; 405:547.
  44. Allen AL, Siegfried EC. What's new in human papillomavirus infection. Curr Opin Pediatr 2000; 12:365.
  45. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3.
  46. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007; 196:1447.
  47. Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206:860.
  48. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805.
  49. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.
  50. Deshmukh AA, Suk R, Shiels MS, et al. Incidence Trends and Burden of Human Papillomavirus-Associated Cancers Among Women in the United States, 2001-2017. J Natl Cancer Inst 2021; 113:792.
  51. Deshmukh AA, Suk R, Shiels MS, et al. Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015. J Natl Cancer Inst 2020; 112:829.
  52. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124:2375.
  53. Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136:98.
  54. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113:2892.
  55. Moscicki AB, Darragh TM, Berry-Lawhorn JM, et al. Screening for Anal Cancer in Women. J Low Genit Tract Dis 2015; 19:S27.
  56. Palefsky JM. Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era. Curr Opin HIV AIDS 2017; 12:26.
  57. Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer 2021; 148:38.
  58. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944.
  59. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344:1125.
  60. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307:693.
  61. Li X, Gao L, Li H, et al. Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis. J Infect Dis 2013; 207:479.
  62. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100:407.
  63. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294.
  64. Van Dyne EA, Henley SJ, Saraiya M, et al. Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015. MMWR Morb Mortal Wkly Rep 2018; 67:918.
  65. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118:1236.
  66. Yuan H, Myers S, Wang J, et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med 2012; 367:1220.
  67. Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44:462.
  68. Karrer S, Szeimies RM, Abels C, et al. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1999; 140:935.
  69. Thomas A, Necchi A, Muneer A, et al. Penile cancer. Nat Rev Dis Primers 2021; 7:11.
  70. Bleeker MC, Heideman DA, Snijders PJ, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009; 27:141.
  71. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20:449.
  72. Melnikow J, Henderson JT, Burda BU, et al. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320:687.
  73. Stier EA, Clarke MA, Deshmukh AA, et al. International Anal Neoplasia Society's consensus guidelines for anal cancer screening. Int J Cancer 2024; 154:1694.
  74. Human Papillomavirus Disease. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human?view=full (Accessed on July 10, 2024).
  75. Arbyn M, Simon M, Peeters E, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect 2021; 27:1083.
  76. Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013; 108:908.
  77. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012; 16:205.
  78. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105:1550.
  79. Rezhake R, Hu SY, Zhao S, et al. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women. Int J Cancer 2019; 144:34.
  80. Bowden SJ, Kalliala I, Veroniki AA, et al. The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: A systematic review and meta-analysis. EBioMedicine 2019; 50:246.
  81. Kelly H, Benavente Y, Pavon MA, et al. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. Br J Cancer 2019; 121:954.
  82. van der Zee RP, Richel O, van Noesel CJM, et al. Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-Positive Men by Validated Methylation Markers Associated With Progression to Cancer. Clin Infect Dis 2021; 72:2154.
  83. Desai KT, Ajenifuja KO, Banjo A, et al. Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infect Agent Cancer 2020; 15:60.
  84. Wang SS, Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003; :35.
  85. Carrington M, Wang S, Martin MP, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 2005; 201:1069.
  86. Centers for Disease Control and Prevention. Genital HPV Infection – Fact Sheet. http://www.cdc.gov/std/HPV/STDFact-HPV.htm (Accessed on April 27, 2012).
  87. Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020; 383:1340.
  88. Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021; 398:2084.
  89. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085.
  90. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645.
  91. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39.
  92. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544.
  93. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385.
  94. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458.
  95. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106:djt460.
  96. Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis 2015; 211:91.
  97. Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics 2015; 135:e1131.
  98. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565.
  99. Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics 2016; 137:e20151968.
  100. Hofstetter AM, Ompad DC, Stockwell MS, et al. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females. JAMA Pediatr 2016; 170:445.
  101. Garland SM, Kjaer SK, Muñoz N, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis 2016; 63:519.
  102. Berenson AB, Laz TH, Rahman M. Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012. J Infect Dis 2016; 214:1961.
  103. Machalek DA, Chow EP, Garland SM, et al. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis 2017; 215:202.
  104. Kahn JA, Widdice LE, Ding L, et al. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clin Infect Dis 2016; 63:1281.
  105. Baussano I, Tshomo U, Tenet V, et al. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study. Ann Intern Med 2020; 173:888.
  106. Rosenblum HG, Lewis RM, Gargano JW, et al. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018. MMWR Morb Mortal Wkly Rep 2021; 70:415.
  107. Markowitz LE, Naleway AL, Lewis RM, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine 2019; 37:3918.
  108. Stefanos R, Lewis RM, Querec TD, et al. High impact of quadrivalent human papillomavirus vaccine across racial/ethnic groups: National Health and Nutrition Examination Survey, 2003-2006 and 2015-2018. Hum Vaccin Immunother 2024; 20:2308378.
  109. Pillsbury AJ, Quinn HE, Evans TD, et al. Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance. Clin Infect Dis 2017; 65:827.
  110. Feiring B, Laake I, Christiansen IK, et al. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway. J Infect Dis 2018; 218:1900.
  111. Spinner C, Ding L, Bernstein DI, et al. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics 2019; 143.
  112. Rosenblum HG, Lewis RM, Gargano JW, et al. Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018. Ann Intern Med 2022; 175:918.
  113. Zhao R, Prizment A, Kulasingam S. Lower human papillomavirus vaccine initiation and completion among Asian American adolescents compared to their peers: National Health and Nutritional Examination Survey 2011-2018. Cancer Causes Control 2023; 34:543.
  114. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218.
  115. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197:279.
  116. Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198:971.
  117. Hariri S, Unger ER, Powell SE, et al. Human papillomavirus genotypes in high-grade cervical lesions in the United States. J Infect Dis 2012; 206:1878.
  118. Banister CE, Messersmith AR, Cai B, et al. Disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age. J Infect Dis 2015; 211:100.
  119. Liu G, Unger ER, Hariri S, et al. Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003-2006. Sex Transm Dis 2016; 43:633.
  120. Pingali C, Yankey D, Elam-Evans LD, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:1183.
  121. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7:453.
  122. One-dose human papillomavirus (HPV) vaccine offers solid protection against cervical cancer. World Health Organization. 2022. https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer (Accessed on June 26, 2024).
  123. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991.
  124. Banura C, Franceschi S, Doorn LJ, et al. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 2008; 197:555.
  125. Oakeshott P, Aghaizu A, Reid F, et al. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ 2012; 344:e4168.
  126. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003; 348:489.
  127. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1796.
  128. Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012; 131:2929.
  129. Gravitt PE, Rositch AF, Silver MI, et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013; 207:272.
  130. Rositch AF, Burke AE, Viscidi RP, et al. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 2012; 72:6183.
  131. Brown DR, Weaver B. Human papillomavirus in older women: new infection or reactivation? J Infect Dis 2013; 207:211.
  132. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577.
  133. Shvetsov YB, Hernandez BY, McDuffie K, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis 2009; 48:536.
  134. Castro FA, Quint W, Gonzalez P, et al. Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica. J Infect Dis 2012; 206:1103.
  135. Beachler DC, D'Souza G, Sugar EA, et al. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 2013; 208:330.
  136. Gaisa M, Ita-Nagy F, Sigel K, et al. High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines. Clin Infect Dis 2017; 64:289.
  137. Wei F, Xia N, Ocampo R, et al. Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies. J Infect Dis 2023; 227:488.
  138. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183:383.
  139. Kojic EM, Conley L, Bush T, et al. Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. J Infect Dis 2018; 217:1544.
  140. Chiao EY, Lensing SY, Wiley DJ, et al. Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV. AIDS 2020; 34:2249.
  141. Goodman MT, Shvetsov YB, McDuffie K, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis 2008; 197:957.
  142. Goodman MT, Shvetsov YB, McDuffie K, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis 2010; 201:1331.
  143. Lin C, Slama J, Gonzalez P, et al. Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infect Dis 2019; 19:880.
  144. Moscicki AB, Ma Y, Farhat S, et al. Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence. Clin Infect Dis 2014; 58:804.
  145. Chiao EY. Duration of anal human papillomavirus infection among immunocompetent women: clues to anal cancer epidemiology and possible prevention strategies. Clin Infect Dis 2009; 48:547.
  146. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 Suppl 3:S3/52.
  147. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2004; 189:46.
  148. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423.
  149. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183:1554.
  150. Karlsson R, Jonsson M, Edlund K, et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995; 22:119.
  151. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995.
  152. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991; 83:997.
  153. Houlihan CF, de Sanjosé S, Baisley K, et al. Prevalence of human papillomavirus in adolescent girls before reported sexual debut. J Infect Dis 2014; 210:837.
  154. Smith JS. Prevalence of human papillomavirus infection in adolescent girls before reported sexual debut. J Infect Dis 2014; 210:835.
  155. Shew ML, Weaver B, Tu W, et al. High frequency of human papillomavirus detection in the vagina before first vaginal intercourse among females enrolled in a longitudinal cohort study. J Infect Dis 2013; 207:1012.
  156. Widdice LE, Breland DJ, Jonte J, et al. Human papillomavirus concordance in heterosexual couples. J Adolesc Health 2010; 47:151.
  157. Simpson S Jr, Blomfield P, Cornall A, et al. Front-to-back & dabbing wiping behaviour post-toilet associated with anal neoplasia & HR-HPV carriage in women with previous HPV-mediated gynaecological neoplasia. Cancer Epidemiol 2016; 42:124.
  158. Nyitray AG, Menezes L, Lu B, et al. Genital human papillomavirus (HPV) concordance in heterosexual couples. J Infect Dis 2012; 206:202.
  159. Nyitray AG, Lin HY, Fulp WJ, et al. The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission. J Infect Dis 2014; 209:1007.
  160. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 2006; 194:1044.
  161. Castellsagué X, Naud P, Chow SN, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis 2014; 210:517.
  162. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102:1653.
  163. Wilson L, Pawlita M, Castle PE, et al. Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis 2014; 210:448.
  164. Safaeian M, Castellsagué X, Hildesheim A, et al. Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. J Infect Dis 2018; 218:84.
  165. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911.
  166. Franceschi S, Baussano I. Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era. J Infect Dis 2014; 210:507.
  167. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011; 204:94.
  168. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354:2645.
  169. Averbach SH, Ma Y, Smith-McCune K, et al. The effect of intrauterine devices on acquisition and clearance of human papillomavirus. Am J Obstet Gynecol 2017; 216:386.e1.
  170. Bruni L, Albero G, Rowley J, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health 2023; 11:e1345.
  171. Kusters JMA, Brouwer JGM, van Benthem BHB, et al. Global Type-Specific Genital Human Papillomavirus Prevalence in Men, by Sexual Orientation: A Systematic Review and Meta-Analysis. J Infect Dis 2023; 228:1023.
  172. US Department of Health and Human Services. Prevalence of HPV in adults aged 18–69: United States, 2011–2014. NCHS Data brief. No 80. April 2017. https://www.cdc.gov/nchs/data/databriefs/db280.pdf (Accessed on April 13, 2017).
  173. Baldwin SB, Wallace DR, Papenfuss MR, et al. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 2004; 31:601.
  174. Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346:1105.
  175. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis 2011; 203:49.
  176. Vardas E, Giuliano AR, Goldstone S, et al. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis 2011; 203:58.
  177. Goldstone S, Palefsky JM, Giuliano AR, et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis 2011; 203:66.
  178. Repp KK, Nielson CM, Fu R, et al. Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States. J Infect Dis 2012; 205:1287.
  179. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13:487.
  180. Liu M, Liu F, Pan Y, et al. Viral Load in the Natural History of Human Papillomavirus Infection Among Men in Rural China: A Population-based Prospective Study. Clin Infect Dis 2018; 67:1861.
  181. Hernandez BY, Shvetsov YB, Goodman MT, et al. Reduced clearance of penile human papillomavirus infection in uncircumcised men. J Infect Dis 2010; 201:1340.
  182. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004; 190:2070.
  183. Glick SN, Feng Q, Popov V, et al. High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. J Infect Dis 2014; 209:369.
  184. Zou H, Tabrizi SN, Grulich AE, et al. Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. J Infect Dis 2014; 209:642.
  185. Nyitray AG, Fujimoto K, Zhao J, et al. Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in a Sample of Young, Predominantly Black Men Who Have Sex With Men, Houston, Texas. J Infect Dis 2018; 217:777.
  186. Tota JE, Giuliano AR, Goldstone SE, et al. Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial. Clin Infect Dis 2022; 74:1247.
  187. Nyitray AG, da Silva RJ, Baggio ML, et al. The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sex Transm Dis 2011; 38:932.
  188. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377:932.
  189. Nielson CM, Harris RB, Dunne EF, et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis 2007; 196:1137.
  190. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196:1128.
  191. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198:827.
  192. Tobian AA, Kigozi G, Gravitt PE, et al. Human papillomavirus incidence and clearance among HIV-positive and HIV-negative men in sub-Saharan Africa. AIDS 2012; 26:1555.
  193. Wei F, Gaisa MM, D'Souza G, et al. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV 2021; 8:e531.
  194. Pamnani SJ, Nyitray AG, Abrahamsen M, et al. Sequential Acquisition of Anal Human Papillomavirus (HPV) Infection Following Genital Infection Among Men Who Have Sex With Women: The HPV Infection in Men (HIM) Study. J Infect Dis 2016; 214:1180.
  195. Larke N, Thomas SL, Dos Santos Silva I, Weiss HA. Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. J Infect Dis 2011; 204:1375.
  196. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis 2007; 196:1146.
  197. Hernandez BY, Wilkens LR, Zhu X, et al. Circumcision and human papillomavirus infection in men: a site-specific comparison. J Infect Dis 2008; 197:787.
  198. Pickard RK, Xiao W, Broutian TR, et al. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis 2012; 39:559.
  199. Lang Kuhs KA, Gonzalez P, Struijk L, et al. Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. J Infect Dis 2013; 208:1643.
  200. Steinau M, Hariri S, Gillison ML, et al. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis 2014; 209:1739.
  201. Sonawane K, Suk R, Chiao EY, et al. Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Ann Intern Med 2017; 167:714.
  202. Chaturvedi AK, Graubard BI, Pickard RK, et al. High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010. J Infect Dis 2014; 210:441.
  203. Fakhry C, Gillison ML, D'Souza G. Tobacco use and oral HPV-16 infection. JAMA 2014; 312:1465.
  204. Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013; 382:877.
  205. Harrison R, Huh W. Occupational Exposure to Human Papillomavirus and Vaccination for Health Care Workers. Obstet Gynecol 2020; 136:663.
  206. Sawchuk WS, Weber PJ, Lowy DR, Dzubow LM. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989; 21:41.
  207. Zhou Q, Hu X, Zhou J, et al. Human papillomavirus DNA in surgical smoke during cervical loop electrosurgical excision procedures and its impact on the surgeon. Cancer Manag Res 2019; 11:3643.
  208. Garden JM, O'Banion MK, Bakus AD, Olson C. Viral disease transmitted by laser-generated plume (aerosol). Arch Dermatol 2002; 138:1303.
  209. Hu X, Zhou Q, Yu J, et al. Prevalence of HPV infections in surgical smoke exposed gynecologists. Int Arch Occup Environ Health 2021; 94:107.
  210. Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur Arch Otorhinolaryngol 1991; 248:425.
  211. Rioux M, Garland A, Webster D, Reardon E. HPV positive tonsillar cancer in two laser surgeons: case reports. J Otolaryngol Head Neck Surg 2013; 42:54.
  212. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013; 8:e68329.
  213. Schlecht NF, Masika M, Diaz A, et al. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine. JAMA Netw Open 2019; 2:e1914031.
  214. Chaturvedi AK, Graubard BI, Broutian T, et al. Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016. JAMA 2019; 322:977.
  215. Singh DK, Anastos K, Hoover DR, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009; 199:1851.
  216. Mbulawa ZZ, Coetzee D, Marais DJ, et al. Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. J Infect Dis 2009; 199:1514.
  217. Mbulawa ZZ, Marais DJ, Johnson LF, et al. Impact of human immunodeficiency virus on the natural history of human papillomavirus genital infection in South African men and women. J Infect Dis 2012; 206:15.
  218. Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis 2013; 208:454.
  219. Sahasrabuddhe VV, Castle PE, Follansbee S, et al. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis 2013; 207:392.
  220. Phanuphak N, Teeratakulpisarn N, Pankam T, et al. Anal human papillomavirus infection among Thai men who have sex with men with and without HIV infection: prevalence, incidence, and persistence. J Acquir Immune Defic Syndr 2013; 63:472.
  221. Welling CA, Mooij SH, van der Sande MA, et al. Association of HIV Infection With Anal and Penile Low-Risk Human Papillomavirus Infections Among Men Who Have Sex With Men in Amsterdam: The HIV & HPV in MSM Study. Sex Transm Dis 2015; 42:297.
  222. Mooij SH, van Santen DK, Geskus RB, et al. The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM. AIDS 2016; 30:121.
  223. Konopnicki D, Manigart Y, Gilles C, et al. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis 2013; 207:1723.
  224. van der Snoek EM, van der Ende ME, den Hollander JC, et al. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex Transm Dis 2012; 39:495.
  225. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010; 201:681.
  226. Palefsky JM. Antiretroviral therapy and anal cancer: the good, the bad, and the unknown. Sex Transm Dis 2012; 39:501.
  227. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547.
  228. Chin-Hong PV, Husnik M, Cranston RD, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009; 23:1135.
  229. Smith JS, Moses S, Hudgens MG, et al. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis 2010; 201:1677.
  230. Tobian AA, Grabowski MK, Kigozi G, et al. Human papillomavirus clearance among males is associated with HIV acquisition and increased dendritic cell density in the foreskin. J Infect Dis 2013; 207:1713.
  231. Houlihan CF, Larke NL, Watson-Jones D, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 2012; 26:2211.
  232. Averbach SH, Gravitt PE, Nowak RG, et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 2010; 24:1035.
  233. Liu G, Mugo NR, Brown ER, et al. Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization. AIDS 2022; 36:257.
Topic 8314 Version 71.0

References

1 : Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection.

2 : Cell surface-binding motifs of L2 that facilitate papillomavirus infection.

3 : Molecular biology of human papillomavirus infection and cervical cancer.

4 : Prophylactic human papillomavirus vaccines.

5 : Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.

6 : Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus.

7 : Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.

8 : A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.

9 : Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.

10 : Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT).

11 : Age-appropriate use of human papillomavirus vaccines in the U.S.

12 : The biology of papillomavirus latency.

13 : Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans.

14 : The human Papillomavirus twilight zone - Latency, immune control and subclinical infection.

15 : High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding.

16 : Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening.

17 : Evidence of latent HPV infection in older Danish women with a previous history of cervical dysplasia.

18 : Human papillomavirus. Epidemiology, transmission, and pathogenesis.

19 : Human papillomavirus. Epidemiology, transmission, and pathogenesis.

20 : Nongenital human papillomavirus infections.

21 : European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts.

22 : Human papillomavirus and cervical cancer.

23 : Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.

24 : Advances in the diagnosis and treatment of human papillomavirus infections.

25 : Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA.

26 : Anal human papillomavirus and anal cancer.

27 : A population-based study of vaginal human papillomavirus infection in hysterectomized women.

28 : Risk of human papillomavirus-associated cancers among persons with AIDS.

29 : Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

30 : Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

31 : Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

32 : Human papillomavirus infection with particular reference to genital disease.

33 : Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.

34 : Epidemiologic classification of human papillomavirus types associated with cervical cancer.

35 : Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

36 : Global burden of human papillomavirus and related diseases.

37 : Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva.

38 : Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.

39 : Human papillomavirus genotype in cervical intraepithelial neoplasia grades 2 and 3 of Taiwanese women.

40 : Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.

41 : A panel of p16(INK4A), MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma.

42 : The role of human papillomavirus infection in the pathogenesis of penile squamous cell carcinomas.

43 : Effects of urethane, ambient temperature and injection route on rat body temperature and metabolism due to endotoxins.

44 : What's new in human papillomavirus infection.

45 : Epidemiology of genital human papillomavirus infection.

46 : The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries.

47 : Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

48 : Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

49 : Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.

50 : Incidence Trends and Burden of Human Papillomavirus-Associated Cancers Among Women in the United States, 2001-2017.

51 : Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015.

52 : Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.

53 : Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.

54 : Understanding the burden of human papillomavirus-associated anal cancers in the US.

55 : Screening for Anal Cancer in Women.

56 : Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era.

57 : A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale.

58 : Case-control study of human papillomavirus and oropharyngeal cancer.

59 : Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.

60 : Prevalence of oral HPV infection in the United States, 2009-2010.

61 : Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis.

62 : Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.

63 : Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

64 : Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015.

65 : Recurrent respiratory papillomatosis: a review.

66 : Use of reprogrammed cells to identify therapy for respiratory papillomatosis.

67 : Imiquimod 5% cream in the treatment of Bowen's disease.

68 : Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy.

69 : Penile cancer.

70 : Penile cancer: epidemiology, pathogenesis and prevention.

71 : Systematic review of human papillomavirus prevalence in invasive penile cancer.

72 : Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

73 : International Anal Neoplasia Society's consensus guidelines for anal cancer screening.

74 : International Anal Neoplasia Society's consensus guidelines for anal cancer screening.

75 : 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.

76 : Comparing the performance of six human papillomavirus tests in a screening population.

77 : The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.

78 : Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.

79 : Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.

80 : The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: A systematic review and meta-analysis.

81 : Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis.

82 : Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-Positive Men by Validated Methylation Markers Associated With Progression to Cancer.

83 : Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage.

84 : Chapter 5: Viral and host factors in human papillomavirus persistence and progression.

85 : Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci.

86 : Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci.

87 : HPV Vaccination and the Risk of Invasive Cervical Cancer.

88 : The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.

89 : Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

90 : Fall in human papillomavirus prevalence following a national vaccination program.

91 : Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

92 : The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.

93 : Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

94 : Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.

95 : Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.

96 : Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data.

97 : The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.

98 : Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

99 : Prevalence of HPV After Introduction of the Vaccination Program in the United States.

100 : Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.

101 : Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.

102 : Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012.

103 : Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program.

104 : Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.

105 : Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.

106 : Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.

107 : Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.

108 : High impact of quadrivalent human papillomavirus vaccine across racial/ethnic groups: National Health and Nutrition Examination Survey, 2003-2006 and 2015-2018.

109 : Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.

110 : Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.

111 : Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women.

112 : Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.

113 : Lower human papillomavirus vaccine initiation and completion among Asian American adolescents compared to their peers: National Health and Nutritional Examination Survey 2011-2018.

114 : Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

115 : Risk of female human papillomavirus acquisition associated with first male sex partner.

116 : Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students.

117 : Human papillomavirus genotypes in high-grade cervical lesions in the United States.

118 : Disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age.

119 : Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003-2006.

120 : National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2020.

121 : Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.

122 : Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.

123 : Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.

124 : Infection with human papillomavirus and HIV among young women in Kampala, Uganda.

125 : Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study.

126 : Adding a test for human papillomavirus DNA to cervical-cancer screening.

127 : Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica.

128 : Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies.

129 : A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States.

130 : Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women.

131 : Human papillomavirus in older women: new infection or reactivation?

132 : Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.

133 : Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study.

134 : Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.

135 : Natural history of anal vs oral HPV infection in HIV-infected men and women.

136 : High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines.

137 : Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies.

138 : Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.

139 : Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study.

140 : Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV.

141 : Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study.

142 : Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study.

143 : Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.

144 : Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.

145 : Duration of anal human papillomavirus infection among immunocompetent women: clues to anal cancer epidemiology and possible prevention strategies.

146 : Chapter 6: Epidemiology and transmission dynamics of genital HPV infection.

147 : Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population.

148 : Natural history of cervicovaginal papillomavirus infection in young women.

149 : Determinants of genital human papillomavirus detection in a US population.

150 : Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study.

151 : Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.

152 : Determinants of genital human papillomavirus infection in young women.

153 : Prevalence of human papillomavirus in adolescent girls before reported sexual debut.

154 : Prevalence of human papillomavirus infection in adolescent girls before reported sexual debut.

155 : High frequency of human papillomavirus detection in the vagina before first vaginal intercourse among females enrolled in a longitudinal cohort study.

156 : Human papillomavirus concordance in heterosexual couples.

157 : Front-to-back&dabbing wiping behaviour post-toilet associated with anal neoplasia&HR-HPV carriage in women with previous HPV-mediated gynaecological neoplasia.

158 : Genital human papillomavirus (HPV) concordance in heterosexual couples.

159 : The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission.

160 : Prevalence of HPV infection among men: A systematic review of the literature.

161 : Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

162 : Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

163 : Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.

164 : Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials.

165 : Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

166 : Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era.

167 : A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.

168 : Condom use and the risk of genital human papillomavirus infection in young women.

169 : The effect of intrauterine devices on acquisition and clearance of human papillomavirus.

170 : Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis.

171 : Global Type-Specific Genital Human Papillomavirus Prevalence in Men, by Sexual Orientation: A Systematic Review and Meta-Analysis.

172 : Global Type-Specific Genital Human Papillomavirus Prevalence in Men, by Sexual Orientation: A Systematic Review and Meta-Analysis.

173 : Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic.

174 : Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners.

175 : Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study.

176 : External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents.

177 : Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men.

178 : Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States.

179 : Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis.

180 : Viral Load in the Natural History of Human Papillomavirus Infection Among Men in Rural China: A Population-based Prospective Study.

181 : Reduced clearance of penile human papillomavirus infection in uncircumcised men.

182 : Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study.

183 : High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men.

184 : Early acquisition of anogenital human papillomavirus among teenage men who have sex with men.

185 : Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in a Sample of Young, Predominantly Black Men Who Have Sex With Men, Houston, Texas.

186 : Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial.

187 : The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study.

188 : Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study.

189 : Risk factors for anogenital human papillomavirus infection in men.

190 : Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students.

191 : Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.

192 : Human papillomavirus incidence and clearance among HIV-positive and HIV-negative men in sub-Saharan Africa.

193 : Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies.

194 : Sequential Acquisition of Anal Human Papillomavirus (HPV) Infection Following Genital Infection Among Men Who Have Sex With Women: The HPV Infection in Men (HIM) Study.

195 : Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis.

196 : The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study.

197 : Circumcision and human papillomavirus infection in men: a site-specific comparison.

198 : The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years.

199 : Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.

200 : Prevalence of cervical and oral human papillomavirus infections among US women.

201 : Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014.

202 : High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010.

203 : Tobacco use and oral HPV-16 infection.

204 : Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study.

205 : Occupational Exposure to Human Papillomavirus and Vaccination for Health Care Workers.

206 : Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection.

207 : Human papillomavirus DNA in surgical smoke during cervical loop electrosurgical excision procedures and its impact on the surgeon.

208 : Viral disease transmitted by laser-generated plume (aerosol).

209 : Prevalence of HPV infections in surgical smoke exposed gynecologists.

210 : Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon.

211 : HPV positive tonsillar cancer in two laser surgeons: case reports.

212 : Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

213 : Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine.

214 : Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016.

215 : Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women.

216 : Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection.

217 : Impact of human immunodeficiency virus on the natural history of human papillomavirus genital infection in South African men and women.

218 : Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women.

219 : Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men.

220 : Anal human papillomavirus infection among Thai men who have sex with men with and without HIV infection: prevalence, incidence, and persistence.

221 : Association of HIV Infection With Anal and Penile Low-Risk Human Papillomavirus Infections Among Men Who Have Sex With Men in Amsterdam: The HIV&HPV in MSM Study.

222 : The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM.

223 : Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.

224 : Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men.

225 : Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women.

226 : Antiretroviral therapy and anal cancer: the good, the bad, and the unknown.

227 : Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy.

228 : Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men.

229 : Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection.

230 : Human papillomavirus clearance among males is associated with HIV acquisition and increased dendritic cell density in the foreskin.

231 : Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis.

232 : The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe.

233 : Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization.